Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Sold by Bronte Capital Management Pty Ltd.

Bronte Capital Management Pty Ltd. lessened its position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 1.7% during the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 137,042 shares of the biopharmaceutical company’s stock after selling 2,412 shares during the period. Regeneron Pharmaceuticals comprises 12.5% of Bronte Capital Management Pty Ltd.’s portfolio, making the stock its 3rd largest position. Bronte Capital Management Pty Ltd.’s holdings in Regeneron Pharmaceuticals were worth $144,064,000 at the end of the most recent quarter.

Other hedge funds also recently made changes to their positions in the company. Brown Lisle Cummings Inc. lifted its position in Regeneron Pharmaceuticals by 18.2% in the 2nd quarter. Brown Lisle Cummings Inc. now owns 65 shares of the biopharmaceutical company’s stock valued at $68,000 after purchasing an additional 10 shares during the last quarter. Sachetta LLC boosted its position in shares of Regeneron Pharmaceuticals by 71.4% during the second quarter. Sachetta LLC now owns 24 shares of the biopharmaceutical company’s stock worth $26,000 after buying an additional 10 shares during the period. Adirondack Trust Co. grew its holdings in Regeneron Pharmaceuticals by 2.4% in the 3rd quarter. Adirondack Trust Co. now owns 431 shares of the biopharmaceutical company’s stock worth $453,000 after buying an additional 10 shares in the last quarter. UMB Bank n.a. increased its position in Regeneron Pharmaceuticals by 1.1% in the 3rd quarter. UMB Bank n.a. now owns 908 shares of the biopharmaceutical company’s stock valued at $955,000 after acquiring an additional 10 shares during the period. Finally, Angeles Wealth Management LLC raised its stake in Regeneron Pharmaceuticals by 3.5% during the 1st quarter. Angeles Wealth Management LLC now owns 325 shares of the biopharmaceutical company’s stock valued at $313,000 after acquiring an additional 11 shares in the last quarter. Institutional investors and hedge funds own 83.31% of the company’s stock.

Regeneron Pharmaceuticals Price Performance

REGN opened at $825.68 on Tuesday. The stock has a fifty day moving average price of $1,021.70 and a 200 day moving average price of $1,038.20. The company has a current ratio of 5.28, a quick ratio of 4.46 and a debt-to-equity ratio of 0.09. Regeneron Pharmaceuticals, Inc. has a 1 year low of $784.96 and a 1 year high of $1,211.20. The stock has a market cap of $90.73 billion, a price-to-earnings ratio of 20.43, a PEG ratio of 3.13 and a beta of 0.15.

Insider Transactions at Regeneron Pharmaceuticals

In related news, CFO Christopher R. Fenimore sold 5,680 shares of the business’s stock in a transaction that occurred on Wednesday, August 28th. The stock was sold at an average price of $1,205.33, for a total value of $6,846,274.40. Following the completion of the sale, the chief financial officer now owns 15,305 shares of the company’s stock, valued at approximately $18,447,575.65. The trade was a 0.00 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Company insiders own 7.48% of the company’s stock.

Wall Street Analyst Weigh In

REGN has been the topic of several research analyst reports. JPMorgan Chase & Co. lowered their target price on shares of Regeneron Pharmaceuticals from $1,200.00 to $1,150.00 and set an “overweight” rating on the stock in a research note on Thursday, October 24th. Leerink Partnrs downgraded Regeneron Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, September 24th. Truist Financial cut their price objective on Regeneron Pharmaceuticals from $1,137.00 to $1,126.00 and set a “buy” rating for the company in a report on Friday, November 1st. Oppenheimer lowered their target price on Regeneron Pharmaceuticals from $1,150.00 to $1,000.00 and set an “outperform” rating on the stock in a report on Wednesday, November 6th. Finally, BMO Capital Markets cut their price target on shares of Regeneron Pharmaceuticals from $1,300.00 to $1,190.00 and set an “outperform” rating for the company in a report on Friday, November 1st. One investment analyst has rated the stock with a sell rating, three have issued a hold rating and eighteen have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $1,107.25.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.